GlucoTrack, Inc. (GCTK) Stock Analysis
Verdict: AVOID
Pre-revenue microcap with <6 months cash runway faces imminent dilution or insolvency despite non-invasive tech potential.
Investment score: 12/100
Analysis as of
Is GlucoTrack, Inc. stock worth reviewing? AI model thesis
GlucoTrack is a high-risk medical technology microcap with zero revenue and a concerning cash burn rate. While the underlying non-invasive technology addresses a massive market, the financial statements reveal a company in distress, characterized by negative equity (-$13M in 2024) and recent share count expansion (from 185k to 899k in two years). The recent volume-heavy price action is typical of 'penny stock' volatility rather than fundamental improvement.
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 20/100 (weight 15%)
- Earnings Quality: 5/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 10/100 (weight 10%)
- Risk-Adjusted Return: 5/100 (weight 15%)
GlucoTrack, Inc. opportunities and risks
What speaks for GCTK
- Non-Invasive Disruption
What speaks against GCTK
- Imminent Cash Exhaustion
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| GCTK | n/a | 0.0x | 0.2x | 0.0% | 0.0% | -5517.0% |
| NDRA | n/a | 0.0x | n/a | 0.0% | 0.0% | -234.4% |
| BMRA | n/a | 1.2x | n/a | 4.3% | -96.5% | -63.3% |
| INBS | n/a | 0.3x | 0.4x | 32.1% | -296.8% | -989.7% |
| XAIR | n/a | 0.5x | n/a | 3.3% | -433.0% | -467.6% |
| FEED | n/a | 0.2x | 0.1x | -12.4% | -744.2% | -2999.6% |
| Peer median | n/a | 0.3x | n/a | 3.3% | -296.8% | -467.6% |
Frequently asked questions about GlucoTrack, Inc. (GCTK)
Is GCTK stock a good investment?
The cached TradeMates AI model rates GlucoTrack, Inc. as AVOID with an investment score of 12/100. GlucoTrack is a high-risk medical technology microcap with zero revenue and a concerning cash burn rate. While the underlying non-invasive technology addresses a massive market, the financial statements reveal a company in distress, characterized by negative equity (-$13M in 2024) and recent share count expansion (from 185k to 899k in two years). The recent volume-heavy price action is typical of 'penny stock' volatility rather than fundamental improvement. This is algorithmic model output, not personal investment advice.
Is GCTK stock a buy?
The TradeMates model verdict for GCTK is AVOID with an investment score of 12/100. Treat this as a model signal to review, not a personal buy recommendation.